Key facts
- Class: synthetic, non-selective melanocortin receptor agonist (activates MC1R through MC5R).
- Also known as: MT-2, MT-II, melanotan, "the Barbie drug," "tan jab."
- Approval status: not approved by the FDA, MHRA, EMA, or TGA for tanning or any other use.
- Route as sold: unlicensed subcutaneous injection or nasal spray from online vendors.
- Evidence level: small early-phase human pharmacology plus animal data; no large tanning trial; harms documented in case reports.
- Commonly reported effects: nausea, facial flushing, appetite loss, spontaneous erections, darkening of moles.
- Legal status: illegal to sell for human use in the US, UK, EU, and Australia; repeated regulator warnings.
What is Melanotan 2?
Melanotan 2 is a lab-made analogue of alpha-melanocyte-stimulating hormone (α-MSH), one of the body's natural pigment-signaling peptides. Chemists at the University of Arizona designed it in the 1980s while looking for a "sunless tanning" agent — something that would brown the skin without the ultraviolet damage of sunbeds. The molecule is a cyclic, shortened, and far more potent version of α-MSH: it resists breakdown, lingers in the body, and binds melanocortin receptors much harder than the natural hormone it copies. Early human work confirmed it is a superpotent melanotropic peptide.
It reaches buyers as a freeze-dried powder for reconstitution and injection, or increasingly as a nasal spray, under names like MT-2, MT-II, "melanotan," "the Barbie drug," and "tan jabs." None of these products are licensed medicines. One important distinction: Melanotan 2 is not the same as afamelanotide (originally "Melanotan I," sold as Scenesse), a related but longer, differently behaving molecule that is an approved implant for a rare light-sensitivity disease. When people say "melanotan" casually, they almost always mean the unapproved cyclic peptide covered here.
How Melanotan 2 works: the melanocortin system
Skin color is controlled by melanocortin signaling. There are five melanocortin receptors, and each governs something different: MC1R drives skin and hair pigment; MC2R handles adrenal steroid production; MC3R and MC4R regulate appetite, energy balance, and sexual function; and MC5R acts on exocrine glands. Natural α-MSH is relatively selective for the pigment pathway. Melanotan 2 is not — it is a broad, non-selective agonist that switches on the entire receptor family at once.
That non-selectivity is the whole story of the drug, for better and worse. Activating MC1R triggers melanocytes to make more eumelanin, so the skin darkens. But the same molecule simultaneously hits MC3R and MC4R in the brain and periphery, which is why users report appetite suppression, nausea, and spontaneous erections. Melanocortin control of appetite and metabolism is well described in the peptide-hormone literature, and the link between melanocortin receptor agonists, penile erection, and sexual motivation was mapped out in animal studies decades ago. Melanotan 2 does not let you pick just the pigment effect; you get the whole cascade.
Does Melanotan 2 actually work for tanning?
Yes — it does darken skin, and that part is not really in dispute. Activating MC1R increases melanin production, so most users tan, often noticeably. The problem is the gap between "produces a tan" and "proven safe and effective." There is no large randomized controlled trial of Melanotan 2 for cosmetic tanning. The pigmentation evidence is small early-phase pharmacology from the 1990s, animal data, and dermatology case reports — nowhere near the evidence base a regulator would require to market a drug.
Two caveats matter for anyone weighing the claim. First, the tan is inseparable from the systemic melanocortin activation described above; you cannot get the color without the appetite, nausea, and sexual effects riding along. Second, a Melanotan tan is not sun protection. It changes pigment but offers only limited defense against UV, and dermatologists warn it can create false confidence, encouraging longer, unprotected sun and sunbed exposure — the exact behavior that raises skin-cancer risk. If the goal is skin health, the peptide is working against it.
Melanotan 2 side effects reported in the literature
Even at the amounts online sellers suggest, a consistent cluster of effects shows up in reports and reviews of melanocortin-analogue use. The review of risks from unregulated α-MSH analogue use and multiple case series describe the following as common:
- Nausea and vomiting — often within the first hours after a dose.
- Facial flushing and warmth.
- Spontaneous yawning and stretching — a distinctive melanocortin effect.
- Reduced appetite.
- Darkening of existing moles, freckles, and new pigment spots, plus general darkening of the skin, lips, and sometimes the gums or nails.
- Spontaneous, unwanted erections in men.
These are not random. Each one is a predictable consequence of stimulating MC1R, MC3R, and MC4R across the body rather than in the skin alone. They are the "expected" side of the ledger. The reason clinicians treat Melanotan 2 as genuinely risky, though, is the other side.
Serious harms: melanoma, priapism, and rhabdomyolysis
Beyond the everyday nuisance effects, the medical literature contains a steady stream of serious case reports. Individually these are anecdotes; together they form a coherent and worrying safety signal for a compound with no trial data to reassure against it.
Changing moles and dysplastic nevi. Dermatologists have documented existing moles darkening and enlarging, and new atypical moles erupting, after melanotan use. Cousen and colleagues reported eruptive melanocytic naevi following melanotan injection, with lesions that were clinically and dermatoscopically atypical. This is exactly the picture that makes skin-cancer surveillance harder.
Melanoma. Case reports describe melanoma in Melanotan 2 users. Hjuler and Lorentzen reported melanoma associated with the use of melanotan-II in a young woman who combined the peptide with sunbeds, and a 2025 report raised the possibility that nasal-spray use is a risk factor for oral mucosal malignant melanoma. Causation is not proven — these are individual cases — but the biology is uncomfortable: the drug chronically stimulates the very melanocytes from which melanoma arises, and by darkening every mole it can mask the color and border changes that are the earliest warning signs of the disease.
Priapism. Because Melanotan 2 drives the MC4R sexual pathway, prolonged, painful erections are a recognized complication. A published case describes Melanotan II overdose associated with priapism — ischemic priapism is a urological emergency that can cause permanent damage if not treated quickly.
Rhabdomyolysis and systemic toxicity. Nelson and colleagues reported a case of Melanotan II injection resulting in systemic toxicity and rhabdomyolysis: a man who injected a large bolus he had bought online developed sympathomimetic toxicity, kidney dysfunction, and muscle breakdown, and spent three days in intensive care. Isolated reports have additionally described kidney infarction and neurological complications. None of this is common, but none of it should happen from a cosmetic product either.
The unregulated-supply problem
The risks above are compounded by how Melanotan 2 is made and sold. Because it cannot be legally marketed as a medicine for human use, there is no manufacturing oversight, no pharmacopoeial standard, and no batch testing. The published review of unregulated melanocortin-analogue use highlights exactly this: products bought online vary in purity, actual peptide content, sterility, and labeling. A vial may contain more or less peptide than stated, or something else entirely.
Nasal sprays add a second layer of uncertainty, because absorption through the nasal mucosa is unpredictable and hard to gauge. On top of that sit the ordinary hazards of self-injecting a non-sterile product from an unknown source: infection and injection-site reactions. If you want to understand how site handling and rotation are supposed to work for legitimate, clinician-directed injectables, our overview of peptide injection sites covers the general principles — but no technique fixes a drug that is intrinsically unproven and unapproved.
Is Melanotan 2 legal or FDA approved?
Melanotan 2 is not approved by the FDA — or by the UK's MHRA, the European EMA, or Australia's TGA — for tanning or any other purpose. In the United States, the FDA has never cleared it and treats it as a substance that raises significant safety concerns; under the Food, Drug, and Cosmetic Act, an unapproved drug cannot be legally marketed for human use. The UK MHRA and Australia's TGA have issued repeated public warnings urging consumers to avoid melanotan products, and selling or supplying it for human use is unlawful across these markets.
Vendors work around this by labeling the peptide a "research chemical" or "not for human consumption," or by marketing it as a cosmetic. That wording changes the sticker on the vial, not the legal or safety reality. For a fuller picture of how "research chemical" framing and the gray market operate, see our explainer on whether peptides are legal.
The contrast with its chemical cousins is instructive. The melanocortin class can yield approved drugs: bremelanotide (PT-141, brand name Vyleesi) was approved in 2019 for hypoactive sexual desire disorder, backed by a full trial program including a randomized clinical study, and afamelanotide (Scenesse) is an approved implant for erythropoietic protoporphyria. Melanotan 2 simply never went through that process. Its unapproved status is not a technicality waiting to be resolved — it is the result of a drug that was never proven safe.
Melanotan 2 vs PT-141 and afamelanotide
Three melanocortin peptides get confused constantly. They share ancestry but have taken completely different regulatory paths, and the differences come down to which receptors each one favors.
| Compound | Receptor emphasis | Main effect | Approval status |
|---|---|---|---|
| Melanotan 2 (MT-II) | Non-selective, MC1R–MC5R | Skin tanning, plus appetite, sexual, and cardiovascular effects | Not approved anywhere for human use |
| PT-141 / bremelanotide (Vyleesi) | Mainly MC3R / MC4R, low MC1R | Sexual desire and arousal | FDA approved (2019) for hypoactive sexual desire disorder |
| Afamelanotide (Melanotan I / Scenesse) | Mainly MC1R | Photoprotective skin pigmentation | FDA approved (2019) for erythropoietic protoporphyria |
| Alpha-MSH (natural hormone) | Endogenous melanocortin signaling | Baseline pigment and appetite regulation | Not a marketed drug |
The PT-141 story is the clearest illustration. Researchers noticed that Melanotan 2 caused strong sexual arousal as a "side effect" during tanning studies, then engineered a modified molecule that leans on the MC3R/MC4R sexual pathway while shedding most of the MC1R skin activity. That became bremelanotide, and it earned approval. You can read the full picture in our companion article on PT-141 (bremelanotide). The takeaway: the same family produced an FDA-approved medicine and an illegal tanning peptide, and the difference is exactly the trial evidence Melanotan 2 lacks.
If your interest in peptides is really about skin, recovery, or wellness rather than a fast tan, the better-studied options live elsewhere. The copper peptide GHK-Cu has a real cosmetic-science literature, and repair peptides such as BPC-157 and immune-modulating thymosin alpha-1 at least have defined mechanisms under study. None are a green light — but they are not sold on the back of a documented melanoma signal.
Frequently asked questions
Is Melanotan 2 FDA approved?
No. Melanotan 2 has never been approved by the FDA, the UK MHRA, the EMA, or Australia's TGA for tanning or any other use. It is illegal to sell for human consumption in those markets, and the FDA lists it as a substance that raises significant safety concerns. The related drugs bremelanotide and afamelanotide are approved, but Melanotan 2 itself is not.
Does Melanotan 2 actually work for tanning?
It does darken skin by activating the MC1R pigment receptor, so users typically do tan. But there is no large controlled trial proving it works safely; the evidence is small early studies, animal data, and case reports. It also does not replace sunscreen and gives limited UV protection, so a Melanotan tan can create false confidence in the sun.
What are the most common Melanotan 2 side effects?
Frequently reported effects include nausea and vomiting, facial flushing, spontaneous yawning and stretching, appetite loss, darkening of moles and freckles, and spontaneous erections in men. These follow directly from the peptide activating melanocortin receptors throughout the body, not just in the skin.
Can Melanotan 2 cause melanoma or skin cancer?
A causal link is not proven, but it is a real concern. Case reports describe melanoma and eruptive dysplastic moles in Melanotan 2 users, and the peptide chronically stimulates the same pigment cells that give rise to melanoma. By darkening every mole, it can also hide the color and border changes that are early warning signs of skin cancer.
Why does Melanotan 2 cause erections and nausea?
Because it is non-selective. Beyond the MC1R skin receptor, Melanotan 2 activates MC3R and MC4R in the brain and body, which regulate sexual arousal and appetite. That is why spontaneous erections and nausea are common, and it is the same MC4R pathway that the approved drug bremelanotide (PT-141) uses on purpose to treat low sexual desire.
Is Melanotan 2 legal to buy?
It is illegal to sell or supply for human use in the US, UK, EU, and Australia, and regulators have issued repeated warnings. It is often sold online as a 'research chemical', labeled 'not for human consumption', or marketed as a cosmetic, which sidesteps the wording on the label but not the law.
What is the difference between Melanotan 2 and PT-141?
They come from the same melanocortin research. PT-141 (bremelanotide) was engineered from Melanotan 2 to target the MC3R and MC4R sexual-arousal pathway with much less MC1R skin activity, and it is FDA approved for a female sexual disorder. Melanotan 2 hits all melanocortin receptors, is used for tanning, and is not approved for anything.
Is Melanotan 2 safe to use long term?
There is no long-term safety data from controlled trials. What exists instead is a growing set of case reports linking it to melanoma, changing moles, prolonged painful erections needing emergency care, kidney injury, and rhabdomyolysis. Combined with unregulated, variable-purity supply, that makes long-term safety impossible to establish. Discuss any pigment or sexual-health concern with a clinician.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed:
- Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a multiple dose study — PubMed 8637402
- Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues — PubMed 28266027
- Eruptive melanocytic naevi following melanotan injection — PubMed 19575725
- Melanoma associated with the use of melanotan-II — PubMed 24355990
- Melanotan II nasal spray: a possible risk factor for oral mucosal malignant melanoma? — PubMed 40210573
- Melanotan II overdose associated with priapism — PubMed 23537392
- Melanotan II injection resulting in systemic toxicity and rhabdomyolysis — PubMed 23121206
- Melanocortin receptor agonists, penile erection, and sexual motivation — PubMed 11035391
- The role of peptide hormones discovered in the 21st century in the regulation of appetite and metabolism — PubMed 34067710
- Bremelanotide for the treatment of hypoactive sexual desire disorder — PubMed 31599840
- New drug approved for treating hypoactive sexual desire disorder — PubMed 31893927
- Overview of peptides and their potential roles in skin health and aging — PubMed 39777813